Hypothesis | Treating agents | Mechanism of available treatments | Current status | Remarks | References |
---|---|---|---|---|---|
Amyloid cascade hypothesis | Plasma exchange with albumin 1 immunoglobulin | Exchange of plasma to remove the amyloid | Phase-III clinical trial | Ongoing research | |
ALZT-OP1a + ALZT-OP1b | Alleviation of amyloid plaque related neuroinflammation | Phase-III clinical trial | Ongoing research | ||
Elenbecestat | Removal of amyloid by inhibiting Beta-secretase 1 | Phase-III clinical trial | Ongoing research | ||
Solanezumab | Monoclonal antibodies targeting amyloid plaque | Failed | Lack of efficacy | ||
Verubecestat | Removal of amyloid by inhibiting Beta-secretase 1 | Failed | Lack of efficacy | ||
Lanabecestat | Removal of amyloid by inhibiting Beta-secretase 1 | Failed | Lack of efficacy | ||
CAD106 | Vaccine-based therapy | Phase-II clinical trial | Ongoing research | ||
CNP520 | Inhibition of Beta-secretase 1 | Phase-II clinical trial | Ongoing research | ||
Crenezumab | Monoclonal antibody targeting amyloid plaque | Ongoing investigation | Ongoing research | ||
Neflamapimod | Inhibition of inflammatory protein p38α MAPK | Ongoing investigation | Ongoing research | ||
Aducanumab | Monoclonal antibody targeting amyloid plaque | Phase-III clinical trial | Ongoing research | ||
Oxidative stress hypothesis | Supplementation of Vitamin C and Vitamin E | Antioxidant to neutralize the ROS | Current investigational treatment | Ongoing study | |
Selenium | Antioxidant to neutralize the ROS | Ongoing investigation | Ongoing study | ||
Curcumin | Antioxidant to neutralize the ROS | Current investigational treatment | Ongoing study | ||
Ginko biloba | Antioxidant to neutralize the ROS | Current treatment | Most effective among the available treatments | ||
Ebenone | Antioxidant to neutralize the ROS | Ongoing investigation | Ongoing study | ||
Estrogen | Antioxidant to neutralize the ROS | Ongoing investigation | Ongoing study | ||
Colostrinin | Antioxidant to neutralize the ROS | Ongoing investigation | Ongoing study | ||
Cholinergic hypothesis | Tacrine | Inhibition of acetylcholinesterase | Current treatment | Approved by FDA | [12] |
Donepezil | Inhibition of acetylcholinesterase | Current treatment | Approved by FDA | ||
Galantamine | Inhibition of acetylcholinesterase | Current treatment | Approved by FDA | ||
Rivastigmine | Inhibition of acetylcholinesterase | Current treatment | Approved by FDA |